Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LSK BioPharma Inc.

lskbiopharma.com

Latest From LSK BioPharma Inc.

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.

South Korea United States

Elevar Aims For Rivoceranib Turnaround After Positive Phase III Update

Despite failing to meet the primary endpoint in recent top-line Phase III results, Elevar Therapeutics (formerly LSK BioPharma) is hopeful that rivoceranib still has potential in late-stage gastric cancer based on generally positive full efficacy data from the global Phase III study presented at ESMO.

Clinical Trials Cancer

LSKB Still Upbeat On Rivoceranib Despite ANGEL Failure In Late-Line Gastric Cancer

LSKB's rivoceranib has missed its endpoint in a Phase III trial in gastric cancer, but the company remains hopeful it will still be able to get FDA approval of the VEGFR-2 inhibitor in this setting, possibly helped by a small additional trial, although there will be a delay. Studies in other potential indications are also ongoing.

Clinical Trials Cancer

Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna

Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • LSP BioPartners
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • LSK BioPharma Inc.
  • Senior Management
  • Soo Whan Choi, PhD, CFO
    Sung Chul Kim, PhD, Pres.
    Alex S Kim, EVP, Corp. Dev.
    Cheol Hee Park, MD, PhD, Assoc. Dir., Clin. Dev.
  • Contact Info
  • LSK BioPharma Inc.
    Phone: (801) 303-7440
    8 E. Broadway
    Ste. 611
    Salt Lake City, UT 84111
    USA
UsernamePublicRestriction

Register